JAK1 and ulcerative colitis: JAK inhibitors [127] including tofacitinib (a pan-JAK inhibitor with predominant JAK1/3 activity) and upadacitinib (a selective JAK1 inhibitor) are increasingly used for moderate-to-severe ulcerative colitis (UC), particularly in biologic-exposed patients.